^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Vumon (teniposide)

    i
    Other names: vm 26, VM-26, VM26
    Company:
    BMS
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    7d
    OTUD3-Mediated Deubiquitination Licenses TEX264 to Orchestrate ER-Phagy for KDM5B Degradation in Teniposide Lung Cancer Therapy. (PubMed, Eur J Pharmacol)
    To summarize, these findings demonstrate that Ten effectively inhibits lung cancer and activates immunocytes by KDM5B inhibition, which is regulated by TEX264-associated ER-phagy. Most importantly, OTUD3 serves as an essential target for enhancement of TEX264 stabilization.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • KDM5B (Lysine Demethylase 5B) • TEX26 (Testis Expressed 26)
    |
    Vumon (teniposide)
    1m
    Teniposide + Bevacizumab: A Phase II Study on Efficacy and Safety in Recurrent Glioblastoma (ChiCTR2600115949)
    P2, N=33, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Vumon (teniposide)
    2ms
    STING activation by teniposide: a potential direct mechanism beyond cGAS stimulation. (PubMed, Front Immunol)
    These findings suggest that Teniposide activates STING through a previously unrecognized, cGAS-independent mechanism, while retaining potential for canonical cGAS-STING stimulation. Our combined computational and experimental evidence supports repurposing Teniposide as a STING agonist, highlighting new therapeutic possibilities for innate immune stimulation.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CGAS (Cyclic GMP-AMP Synthase) • IFI16 (Interferon Gamma Inducible Protein 16) • IFNB1 (Interferon Beta 1)
    |
    Vumon (teniposide)
    3ms
    Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=15, Recruiting, Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Jun 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Vumon (teniposide)
    4ms
    Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report. (PubMed, Anticancer Drugs)
    As of June 2025, the patient has achieved a CR with a progression-free survival of 9 months before experiencing disease recurrence. This rare case of NF1-associated oligodendroglioma was managed with thiotepa, bevacizumab, teniposide, and tunlametinib, highlighting the potential of MEK inhibition in NF1-related gliomas.
    Journal
    |
    NF1 (Neurofibromin 1)
    |
    Avastin (bevacizumab) • Kolupin (tunlametinib) • Vumon (teniposide) • thiotepa
    4ms
    Teniposide combined with bevacizumab for the treatment of recurrent high-grade MGMT promoter unmethylated glioma: A single-center prospective study (ChiCTR2500108634)
    P=N/A, N=20, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Avastin (bevacizumab) • Vumon (teniposide)
    6ms
    Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL (clinicaltrials.gov)
    P2/3, N=215, Not yet recruiting, Huashan Hospital
    New P2/3 trial
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • dexamethasone • Vumon (teniposide)
    6ms
    Triggering mitotic catastrophe by podophyllotoxin induces apoptosis in oral squamous cell carcinoma. (PubMed, Arch Oral Biol)
    This study provides compelling evidence supporting the potential therapeutic significance of inducing MC-mediated apoptosis in OSCC. The results underscore the role of PPT and its derivatives, such as etoposide and teniposide, in targeting rapidly dividing cancer cells through interference with mitotic progression, offering insights into novel therapeutic strategies for oral cancer.
    Journal
    |
    CHEK2 (Checkpoint kinase 2) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5) • CCNB1 (Cyclin B1)
    |
    etoposide IV • Vumon (teniposide)
    7ms
    Teniposide Triggers DNA Repair Inhibition by Binding and Ubiquitination of Apurinic/Apyrimidinic Endonuclease 1 to Boost Oxidative DNA Damage for Lung Cancer Destruction. (PubMed, ACS Pharmacol Transl Sci)
    In summary, these data make a strong argument for the notion that Ten/VM-26-mediated inhibition of APEX1 contributes to DNA damage and thereby achieves favorable antilung cancer effects, wherein Ten/VM-26 could down-regulate APEX1 by binding and ubiquitination. The current study presents a critical target and mechanism for Ten/VM-26-mediated antilung cancer therapy.
    Journal
    |
    APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
    |
    Vumon (teniposide)
    7ms
    A single-center, single-arm, open-label study on the treatment of newly diagnosed patients with central malignant germ cell tumors with teniposide injection combined with cisplatin (ChiCTR2500106961)
    P4, N=100, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P4 trial
    |
    cisplatin • Vumon (teniposide)
    8ms
    VPX: Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    Vumon (teniposide) • thiotepa • busulfan
    8ms
    Rituximab in Primary Central Nervous system Lymphoma.nA randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study (ACTRN12610000908033)
    P3, N=80, Completed, HOVON | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • cytarabine • carmustine • Vumon (teniposide)